malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

Since the turn of the century, a remarkable expansion has been achieved in the range and effectiveness of products and strategies available to prevent, treat, and control malaria, including advances in diagnostics, drugs, vaccines, and vector control. These advances have once again put malaria elimination on the agenda. However, it is clear that even with the means available today, malaria control and elimination pose a formidable challenge in many settings. Thus, currently available resources must be used more effectively, and new products and approaches likely to achieve these goals must be developed. This paper considers tools (both those available and others that may be required) to achieve and maintain malaria elimination. New diagnostics are needed to direct treatment and detect transmission potential; new drugs and vaccines to overcome existing resistance and protect against clinical and severe disease, as well as block transmission and prevent relapses; and new vector control measures to overcome insecticide resistance and more powerfully interrupt transmission. It is also essential that strategies for combining new and existing approaches are developed for different settings to maximise their longevity and effectiveness in areas with continuing transmission and receptivity. For areas where local elimination has been recently achieved, understanding which measures are needed to maintain elimination is necessary to prevent rebound and the reestablishment of transmission. This becomes increasingly important as more countries move towards elimination.

[1]  M. Tanner,et al.  malERA: An updated research agenda for health systems and policy research in malaria elimination and eradication , 2017, PLoS medicine.

[2]  B. F. Hall,et al.  malERA: An updated research agenda for malaria elimination and eradication , 2017, PLoS medicine.

[3]  Modelling,et al.  malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication , 2017, PLoS medicine.

[4]  malERA Refresh Consultative Panel malERA: An updated research agenda for characterising the reservoir and measuring transmission in malaria elimination and eradication , 2017, PLoS medicine.

[5]  K. Paaijmans,et al.  malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication , 2017, PLoS medicine.

[6]  D. Kwiatkowski,et al.  Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. , 2017, The Lancet. Infectious diseases.

[7]  D. Fidock,et al.  A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study , 2017, The Lancet. Infectious diseases.

[8]  J. Burrows,et al.  New developments in anti-malarial target candidate and product profiles , 2017, Malaria Journal.

[9]  Richard J. Maude,et al.  Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria , 2017, PloS one.

[10]  N. White Why Do Some Primate Malarias Relapse? , 2016, Trends in Parasitology.

[11]  Paige E. Waterman,et al.  Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.

[12]  M. Parker,et al.  Development of drugs for severe malaria in children , 2016, International health.

[13]  Division on Earth Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values , 2016 .

[14]  H. Chandel,et al.  Prevalence of pfhrp2 and/or pfhrp3 Gene Deletion in Plasmodium falciparum Population in Eight Highly Endemic States in India , 2016, PloS one.

[15]  S. Meshnick,et al.  Estimation of Plasmodium falciparum Transmission Intensity in Lilongwe, Malawi, by Microscopy, Rapid Diagnostic Testing, and Nucleic Acid Detection. , 2016, The American journal of tropical medicine and hygiene.

[16]  Division on Earth COMMITTEE ON GENE DRIVE RESEARCH IN NON-HUMAN ORGANISMS: RECOMMENDATIONS FOR RESPONSIBLE CONDUCT , 2016 .

[17]  Werayut Srituravanich,et al.  The development of malaria diagnostic techniques: a review of the approaches with focus on dielectrophoretic and magnetophoretic methods , 2016, Malaria Journal.

[18]  Juliana K. Wambua,et al.  Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. , 2016, The New England journal of medicine.

[19]  Frederick R. Haselton,et al.  Mobile phone imaging and cloud-based analysis for standardized malaria detection and reporting , 2016, Scientific Reports.

[20]  C. Rogier,et al.  A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.

[21]  M. Chavchich,et al.  The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites , 2016, Antimicrobial Agents and Chemotherapy.

[22]  A. Dicko,et al.  Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. , 2016, The Lancet. Infectious diseases.

[23]  R. Garfein,et al.  Digital health for the End TB Strategy: developing priority products and making them work , 2016, European Respiratory Journal.

[24]  D. Kwiatkowski,et al.  Elusive Plasmodium Species Complete the Human Malaria Genome Set , 2016, bioRxiv.

[25]  J. McCarthy,et al.  Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects , 2016, British journal of clinical pharmacology.

[26]  K. Bourtzis,et al.  More than one rabbit out of the hat: Radiation, transgenic and symbiont-based approaches for sustainable management of mosquito and tsetse fly populations. , 2016, Acta tropica.

[27]  J. Hemingway,et al.  Averting a malaria disaster: will insecticide resistance derail malaria control? , 2016, The Lancet.

[28]  J. McCarthy,et al.  Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development , 2016, Antimicrobial Agents and Chemotherapy.

[29]  L. von Seidlein,et al.  The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan , 2016, PLoS medicine.

[30]  P. Gething,et al.  Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. , 2016, The Lancet. Infectious diseases.

[31]  Jane M. Carlton,et al.  A Method for Amplicon Deep Sequencing of Drug Resistance Genes in Plasmodium falciparum Clinical Isolates from India , 2016, Journal of Clinical Microbiology.

[32]  A. Tompkins,et al.  A Regional Model for Malaria Vector Developmental Habitats Evaluated Using Explicit, Pond-Resolving Surface Hydrology Simulations , 2016, PloS one.

[33]  T. Bousema,et al.  Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial , 2016, BMC Medicine.

[34]  H. C. Chai,et al.  Development of insulated isothermal PCR for rapid on-site malaria detection , 2016, Malaria Journal.

[35]  J. McCarthy,et al.  Novel molecular diagnostic tools for malaria elimination: a review of options from the point of view of high-throughput and applicability in resource limited settings , 2016, Malaria Journal.

[36]  Andrea Pavesi,et al.  Advances in microfluidics in combating infectious diseases , 2016, Biotechnology Advances.

[37]  K. Miura Progress and prospects for blood-stage malaria vaccines , 2016, Expert review of vaccines.

[38]  O. Doumbo,et al.  Gametocyte clearance dynamics following oral artesunate treatment of uncomplicated falciparum malaria in Malian children , 2016, Parasite.

[39]  Joshua D. Hartzell,et al.  Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy , 2016, PLoS neglected tropical diseases.

[40]  J. Cox,et al.  Plasmodium knowlesi transmission: integrating quantitative approaches from epidemiology and ecology to understand malaria as a zoonosis , 2016, Parasitology.

[41]  O. Doumbo,et al.  Implementation of the malaria candidate vaccine RTS,S/AS01 , 2016, The Lancet.

[42]  Katya Galactionova,et al.  Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models , 2016, The Lancet.

[43]  D. Fidock,et al.  Luciferase-Based, High-Throughput Assay for Screening and Profiling Transmission-Blocking Compounds against Plasmodium falciparum Gametocytes , 2016, Antimicrobial Agents and Chemotherapy.

[44]  Stuart L. Schreiber,et al.  High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission , 2016, Cell host & microbe.

[45]  A. Hill,et al.  Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology , 2016, Scientific Reports.

[46]  C. Chitnis,et al.  Development of vaccines for Plasmodium vivax malaria. , 2015, Vaccine.

[47]  T. Horii,et al.  Recent advances in recombinant protein-based malaria vaccines , 2015, Vaccine.

[48]  D. Kaslow,et al.  RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap. , 2015, Vaccine.

[49]  R. Verity,et al.  Vaccine approaches to malaria control and elimination: Insights from mathematical models. , 2015, Vaccine.

[50]  Andrea Crisanti,et al.  A CRISPR-Cas9 Gene Drive System Targeting Female Reproduction in the Malaria Mosquito vector Anopheles gambiae , 2015, Nature Biotechnology.

[51]  W. Focke,et al.  Acceptability and effectiveness of a monofilament, polyethylene insecticide-treated wall lining for malaria control after six months in dwellings in Vhembe District, Limpopo Province, South Africa , 2015, Malaria Journal.

[52]  S. Li,et al.  Editorial: Why Vaccines to HIV, HCV, and Malaria Have So Far Failed—Challenges to Developing Vaccines Against Immunoregulating Pathogens , 2015, Front. Microbiol..

[53]  Pedro Alonso,et al.  Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines , 2015, Vaccine.

[54]  Ethan Bier,et al.  Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi , 2015, Proceedings of the National Academy of Sciences.

[55]  Christopher V. Plowe Vaccine-Resistant Malaria. , 2015, The New England journal of medicine.

[56]  Trevor Bedford,et al.  Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. , 2015, The New England journal of medicine.

[57]  J. Logedi,et al.  Feasibility of an innovative electronic mobile system to assist health workers to collect accurate, complete and timely data in a malaria control programme in a remote setting in Kenya , 2015, Malaria Journal.

[58]  Brian J. Johnson,et al.  The Siren's Song: Exploitation of Female Flight Tones to Passively Capture Male Aedes aegypti (Diptera: Culicidae) , 2015, Journal of Medical Entomology.

[59]  J. Rubio,et al.  Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping , 2015, The Journal of infectious diseases.

[60]  Ludovic P Ahoua Alou,et al.  Efficacy of Olyset® Duo, a permethrin and pyriproxyfen mixture net against wild pyrethroid-resistant Anopheles gambiae s.s. from Côte d’Ivoire: an experimental hut trial , 2015, Parasite.

[61]  Ludovic P Ahoua Alou,et al.  Insecticidal and sterilizing effect of Olyset Duo®, a permethrin and pyriproxyfen mixture net against pyrethroid-susceptible and -resistant strains of Anopheles gambiae s.s.: a release-recapture assay in experimental huts , 2015, Parasite.

[62]  S. Agnandji,et al.  Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. , 2015, Future microbiology.

[63]  J. Beier,et al.  Formulation of attractive toxic sugar bait (ATSB) with safe EPA-exempt substance significantly diminishes the Anopheles sergentii population in a desert oasis. , 2015, Acta tropica.

[64]  Yuming Guo,et al.  The effect of air pollution on human physiological function in China: a longitudinal study , 2015, The Lancet.

[65]  D K Das,et al.  Computational microscopic imaging for malaria parasite detection: a systematic review , 2015, Journal of microscopy.

[66]  Q. Bassat,et al.  Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model , 2015, PLoS medicine.

[67]  R. Price,et al.  The challenges of introducing routine G6PD testing into radical cure: a workshop report , 2015, Malaria Journal.

[68]  David Malone,et al.  Disruptive technology for vector control: the Innovative Vector Control Consortium and the US Military join forces to explore transformative insecticide application technology for mosquito control programmes , 2015, Malaria Journal.

[69]  U. Dalrymple,et al.  The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015 , 2015, Nature.

[70]  D. Ndiaye,et al.  Malaria Diagnosis across the International Centers of Excellence for Malaria Research: Platforms, Performance, and Standardization , 2015, The American journal of tropical medicine and hygiene.

[71]  H. Ranson,et al.  Electrostatic coating enhances bioavailability of insecticides and breaks pyrethroid resistance in mosquitoes , 2015, Proceedings of the National Academy of Sciences.

[72]  Gonzalo Colmenarejo,et al.  A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery , 2015, PloS one.

[73]  P. Michel,et al.  A systematic, realist review of zooprophylaxis for malaria control , 2015, Malaria Journal.

[74]  S. Hoffman,et al.  Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.

[75]  L. Rénia,et al.  Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax , 2015, Front. Immunol..

[76]  U. d’Alessandro,et al.  Transdermal Diagnosis of Malaria Using Vapor Nanobubbles , 2015, Emerging infectious diseases.

[77]  F. Tripet,et al.  Targeting male mosquito mating behaviour for malaria control , 2015, Parasites & Vectors.

[78]  A. Wilke,et al.  Paratransgenesis: a promising new strategy for mosquito vector control , 2015, Parasites & Vectors.

[79]  Hannah C. Slater,et al.  Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda , 2015, Malaria Journal.

[80]  I. Kleinschmidt,et al.  The evidence for improving housing to reduce malaria: a systematic review and meta-analysis , 2015, Malaria Journal.

[81]  Farah El Mazouni,et al.  A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria , 2015, Science Translational Medicine.

[82]  T. Bousema,et al.  A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs. , 2015, The Journal of antimicrobial chemotherapy.

[83]  P. Rosenthal,et al.  Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso , 2015, Antimicrobial Agents and Chemotherapy.

[84]  Peter G. Kremsner,et al.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .

[85]  O. Vandal,et al.  Killing the hypnozoite – drug discovery approaches to prevent relapse in Plasmodium vivax , 2015, Pathogens and global health.

[86]  S. Hoffman,et al.  Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum , 2015, Malaria Journal.

[87]  A. Vaughan,et al.  Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. , 2015, Cell host & microbe.

[88]  Sujin Lee,et al.  Recent Advances of Vaccine Adjuvants for Infectious Diseases , 2015, Immune network.

[89]  Evelyn Siu,et al.  Modeling malaria in humanized mice: opportunities and challenges , 2015, Annals of the New York Academy of Sciences.

[90]  Stephen C. Trowell,et al.  Analysis of Breath Specimens for Biomarkers of Plasmodium falciparum Infection , 2015, The Journal of infectious diseases.

[91]  D. Leboulleux,et al.  Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine. , 2015, Vaccine.

[92]  R. Sinden,et al.  Imaging-Based High-Throughput Screening Assay To Identify New Molecules with Transmission-Blocking Potential against Plasmodium falciparum Female Gamete Formation , 2015, Antimicrobial Agents and Chemotherapy.

[93]  S. Hoffman,et al.  Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.

[94]  H. Liao,et al.  Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. , 2015, The Journal of infectious diseases.

[95]  Fatimah Ibrahim,et al.  The Application of Biomedical Engineering Techniques to the Diagnosis and Management of Tropical Diseases: A Review , 2015, Sensors.

[96]  P. Garner,et al.  Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission , 2015, The Cochrane database of systematic reviews.

[97]  D. Pillai,et al.  Evaluation of non-instrumented nucleic acid amplification by loop-mediated isothermal amplification (NINA-LAMP) for the diagnosis of malaria in Northwest Ethiopia , 2015, Malaria Journal.

[98]  Abdullah S. Ali,et al.  Loop-mediated isothermal amplification (LAMP) for point-of-care detection of asymptomatic low-density malaria parasite carriers in Zanzibar , 2015, Malaria Journal.

[99]  Teun Bousema,et al.  The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. , 2014, The Journal of infectious diseases.

[100]  I. Elyazar,et al.  Impact of a spatial repellent on malaria incidence in two villages in Sumba, Indonesia. , 2014, The American journal of tropical medicine and hygiene.

[101]  Y. Takwoingi,et al.  Rapid diagnostic tests for diagnosing uncomplicated non‐falciparum or Plasmodium vivax malaria in endemic countries , 2014, The Cochrane database of systematic reviews.

[102]  A. Dao,et al.  Signatures of aestivation and migration in Sahelian malaria mosquito populations , 2014, Nature.

[103]  B. Genton,et al.  Comparison of detection methods to estimate asexual Plasmodium falciparum parasite prevalence and gametocyte carriage in a community survey in Tanzania , 2014, Malaria Journal.

[104]  S. Hay,et al.  Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission , 2014, eLife.

[105]  B. Lige,et al.  The performance evaluation of a urine malaria test (UMT) kit for the diagnosis of malaria in individuals with fever in south-east Nigeria: cross-sectional analytical study , 2014, Malaria Journal.

[106]  S. Meshnick,et al.  Field evaluation of a real-time fluorescence loop-mediated isothermal amplification assay, RealAmp, for the diagnosis of malaria in Thailand and India. , 2014, The Journal of infectious diseases.

[107]  D. Kaslow,et al.  Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward. , 2014, Vaccine.

[108]  G. Killeen,et al.  Characterizing, controlling and eliminating residual malaria transmission , 2014, Malaria Journal.

[109]  W. Focke,et al.  Development of an insecticide impregnated polymer wall lining for malaria vector control , 2014, Malaria Journal.

[110]  G. A. Ngwa,et al.  On a Reproductive Stage-Structured Model for the Population Dynamics of the Malaria Vector , 2014, Bulletin of Mathematical Biology.

[111]  J. Beier,et al.  Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination , 2014, Parasitology Research.

[112]  N. Chandrasekaran,et al.  Study on antimicrobial potential of neem oil nanoemulsion against Pseudomonas aeruginosa infection in Labeo rohita , 2014, Biotechnology and applied biochemistry.

[113]  Baldur P Magnusson,et al.  A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers , 2014, Antimicrobial Agents and Chemotherapy.

[114]  Baldur P Magnusson,et al.  A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers , 2014, Antimicrobial Agents and Chemotherapy.

[115]  Dean P. Jones,et al.  Metabolomics in the fight against malaria , 2014, Memorias do Instituto Oswaldo Cruz.

[116]  Kanika Thakur,et al.  Docetaxel loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies. , 2014, International journal of biological macromolecules.

[117]  Peter Chiodini,et al.  Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting , 2014, Malaria Journal.

[118]  George M Church,et al.  Concerning RNA-guided gene drives for the alteration of wild populations , 2014, bioRxiv.

[119]  Austin Burt,et al.  Heritable strategies for controlling insect vectors of disease , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[120]  C. Ockenhouse,et al.  Controlled human malaria infection. , 2014, The Journal of infectious diseases.

[121]  S. Moore,et al.  A household randomized, controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-lasting insecticidal nets on the incidence of Plasmodium falciparum and Plasmodium vivax malaria in Western Yunnan Province, China , 2014, Malaria Journal.

[122]  A. Mbonye,et al.  A lab-on-chip for malaria diagnosis and surveillance , 2014, Malaria Journal.

[123]  N. Valecha,et al.  Comparison of three PCR-based assays for the non-invasive diagnosis of malaria: detection of Plasmodium parasites in blood and saliva , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[124]  R. Chhem,et al.  Current status and future challenges for controlling malaria with the sterile insect technique: technical and social perspectives. , 2014, Acta tropica.

[125]  M. Harry,et al.  Biting by Anopheles funestus in broad daylight after use of long-lasting insecticidal nets: a new challenge to malaria elimination , 2014, Malaria Journal.

[126]  Malaya K. Sahoo,et al.  Multiplex Nucleic Acid Amplification Test for Diagnosis of Dengue Fever, Malaria, and Leptospirosis , 2014, Journal of Clinical Microbiology.

[127]  S. Krudsood,et al.  Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.

[128]  G. Killeen,et al.  Potential causes and consequences of behavioural resilience and resistance in malaria vector populations: a mathematical modelling analysis , 2014, Malaria Journal.

[129]  P. Rosenthal,et al.  Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda , 2014, Malaria Journal.

[130]  Rakesh K. Sharma,et al.  Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation. , 2014, International journal of pharmaceutics.

[131]  M. Rowland,et al.  Mosquito Nets Treated with a Mixture of Chlorfenapyr and Alphacypermethrin Control Pyrethroid Resistant Anopheles gambiae and Culex quinquefasciatus Mosquitoes in West Africa , 2014, PloS one.

[132]  O. Sarr,et al.  Analysis of pfhrp2 genetic diversity in Senegal and implications for use of rapid diagnostic tests , 2014, Malaria Journal.

[133]  O. Billker,et al.  Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites , 2013, Infection and Immunity.

[134]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[135]  E. Winzeler,et al.  Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. , 2013, The Journal of infectious diseases.

[136]  M. Rossignol,et al.  Efficacy of Olyset® Plus, a New Long-Lasting Insecticidal Net Incorporating Permethrin and Piperonil-Butoxide against Multi-Resistant Malaria Vectors , 2013, PloS one.

[137]  C. Rogier,et al.  The changes in mosquito vector behaviour and the emerging resistance to insecticides will challenge the decline of malaria. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[138]  M. P. Griffin,et al.  A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults , 2013, Antimicrobial Agents and Chemotherapy.

[139]  A. M. de Oliveira,et al.  Multiple genetic origins of histidine-rich protein 2 gene deletion in Plasmodium falciparum parasites from Peru , 2013, Scientific Reports.

[140]  Peter Siba,et al.  Strategies for Detection of Plasmodium species Gametocytes , 2013, PloS one.

[141]  Steven W Lindsay,et al.  Mosquito larval source management for controlling malaria. , 2013, The Cochrane database of systematic reviews.

[142]  John M. Marshall,et al.  Quantifying the mosquito’s sweet tooth: modelling the effectiveness of attractive toxic sugar baits (ATSB) for malaria vector control , 2013, Malaria Journal.

[143]  Anne E Carpenter,et al.  A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. , 2013, Cell host & microbe.

[144]  N. Chitnis,et al.  Effects of changing mosquito host searching behaviour on the cost effectiveness of a mass distribution of long-lasting, insecticidal nets: a modelling study , 2013, Malaria Journal.

[145]  A. Jin,et al.  Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. , 2013, Vaccine.

[146]  J. Burrows,et al.  Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.

[147]  Q. Bassat,et al.  Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination , 2013, Malaria Journal.

[148]  C. Mbogo,et al.  The role of Anopheles arabiensis and Anopheles coustani in indoor and outdoor malaria transmission in Taveta District, Kenya , 2013, Parasites & Vectors.

[149]  G. Killeen,et al.  Entomological surveillance of behavioural resilience and resistance in residual malaria vector populations , 2013, Malaria Journal.

[150]  Martin Walker,et al.  Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection , 2013, eLife.

[151]  John M. Marshall,et al.  THE IMPORTANCE OF MOSQUITO BEHAVIOURAL ADAPTATIONS TO MALARIA CONTROL IN AFRICA , 2013, Evolution; international journal of organic evolution.

[152]  N. Hung,et al.  Cost-Effectiveness of Long-Lasting Insecticide-Treated Hammocks in Preventing Malaria in South-Central Vietnam , 2013, PloS one.

[153]  N. Beebe,et al.  Successful malaria elimination strategies require interventions that target changing vector behaviours , 2013, Malaria Journal.

[154]  J. McCarthy,et al.  Experimentally induced blood stage malaria infection as a tool for clinical research. , 2012, Trends in parasitology.

[155]  Søren K Rasmussen,et al.  Recombinant antibody mixtures: production strategies and cost considerations. , 2012, Archives of biochemistry and biophysics.

[156]  O. Doumbo,et al.  Mosquito Feeding Assays to Determine the Infectiousness of Naturally Infected Plasmodium falciparum Gametocyte Carriers , 2012, PloS one.

[157]  R. Price,et al.  Primaquine radical cure of Plasmodium vivax: a critical review of the literature , 2012, Malaria Journal.

[158]  R. Sauerwein,et al.  A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. , 2012, Vaccine.

[159]  A. Ghosh,et al.  Fighting malaria with engineered symbiotic bacteria from vector mosquitoes , 2012, Proceedings of the National Academy of Sciences.

[160]  D. Meyrowitsch,et al.  Change in composition of the Anopheles gambiae complex and its possible implications for the transmission of malaria and lymphatic filariasis in north-eastern Tanzania , 2012, Malaria Journal.

[161]  A. Vaughan,et al.  Development of humanized mouse models to study human malaria parasite infection. , 2012, Future microbiology.

[162]  J. Lelièvre,et al.  Activity of Clinically Relevant Antimalarial Drugs on Plasmodium falciparum Mature Gametocytes in an ATP Bioluminescence “Transmission Blocking” Assay , 2012, Malaria Journal.

[163]  D. Leroy,et al.  Comparison and Optimization of Different Methods for the In Vitro Production of Plasmodium falciparum Gametocytes , 2012, Journal of parasitology research.

[164]  Arantxa Roca-Feltrer,et al.  Estimating the potential public health impact of seasonal malaria chemoprevention in African children , 2012, Nature Communications.

[165]  A. James,et al.  Why RIDL is not SIT. , 2011, Trends in parasitology.

[166]  Adalgisa Caccone,et al.  Outdoor host seeking behaviour of Anopheles gambiae mosquitoes following initiation of malaria vector control on Bioko Island, Equatorial Guinea , 2011, Malaria Journal.

[167]  Tanya L Russell,et al.  Increased proportions of outdoor feeding among residual malaria vector populations following increased use of insecticide-treated nets in rural Tanzania , 2011, Malaria Journal.

[168]  Andrea Crisanti,et al.  A synthetic homing endonuclease-based gene drive system in the human malaria mosquito , 2011, Nature.

[169]  M. Chen-Mok,et al.  Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. , 2011, The American journal of tropical medicine and hygiene.

[170]  Yongyuth Yuthavong,et al.  A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.

[171]  Frank H. Collins,et al.  A Research Agenda for Malaria Eradication: Vector Control , 2011, PLoS medicine.

[172]  Prashant Yadav,et al.  A Research Agenda for Malaria Eradication: Vaccines , 2019 .

[173]  David Schellenberg,et al.  A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.

[174]  M. Rowland,et al.  An experimental hut evaluation of PermaNet(®) 3.0, a deltamethrin-piperonyl butoxide combination net, against pyrethroid-resistant Anopheles gambiae and Culex quinquefasciatus mosquitoes in southern Benin. , 2010, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[175]  Kamolrat Silamut,et al.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial , 2010, The Lancet.

[176]  M. Pascual,et al.  Transmission Intensity and Drug Resistance in Malaria Population Dynamics: Implications for Climate Change , 2010, PloS one.

[177]  Thomas Smith,et al.  Comparing the Effectiveness of Malaria Vector-Control Interventions Through a Mathematical Model , 2010, The American journal of tropical medicine and hygiene.

[178]  J. Baird,et al.  Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. , 2010, Trends in parasitology.

[179]  M. Perkins,et al.  A Large Proportion of P. falciparum Isolates in the Amazon Region of Peru Lack pfhrp2 and pfhrp3: Implications for Malaria Rapid Diagnostic Tests , 2010, PloS one.

[180]  Olivier Pigeon,et al.  Evaluation of PermaNet 3.0 a deltamethrin-PBO combination net against Anopheles gambiae and pyrethroid resistant Culex quinquefasciatus mosquitoes: an experimental hut trial in Tanzania , 2010, Malaria Journal.

[181]  Brian Kelley,et al.  Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.

[182]  C. Plowe,et al.  Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’ , 2009, Parasite immunology.

[183]  J. Carlton,et al.  Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. , 2007, The Journal of infectious diseases.

[184]  M. Gatton,et al.  Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. , 2007, The Journal of infectious diseases.

[185]  J. Verhave,et al.  Age-dependent distribution of Plasmodium falciparum gametocytes quantified by Pfs25 real-time QT-NASBA in a cross-sectional study in Burkina Faso. , 2007, The American journal of tropical medicine and hygiene.

[186]  Arjen Dondorp,et al.  Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial , 2005, The Lancet.

[187]  W. Watkins,et al.  Intensity of malaria transmission and the evolution of drug resistance. , 2005, Acta tropica.

[188]  D. Kaslow,et al.  Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium vivax To Infect Mosquitoes , 2000, Infection and Immunity.

[189]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[190]  B. Maegraith Liverpool School of Tropical Medicine , 1907, Nature.

[191]  B. Birren,et al.  Genetic Diversity and Protective Efficacy of the RTS , S / AS 01 Malaria Vaccine , 2015 .

[192]  Gao Qi,et al.  Global technical strategy for malaria 2016–2030 , 2015 .

[193]  T. Bousema,et al.  Quantification of female and male Plasmodium falciparum gametocytes by reverse transcriptase quantitative PCR. , 2015, Molecular and biochemical parasitology.

[194]  Andrea Crisanti,et al.  A CRISPR-Cas 9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae , 2015 .

[195]  M. Coosemans,et al.  Residual transmission of malaria : an old issue for new approaches , 2013 .

[196]  T. Bousema,et al.  A protocol for membrane feeding assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae , 2013 .

[197]  Weltgesundheitsorganisation World malaria report , 2005 .

[198]  J. A. Downes The Swarming and Mating Flight of Diptera , 1969 .